Genmab-Led Acquisition Targets Dutch Biotech with M&A Catalyst for Cancer Treatment

27 days ago

Tom Keen/Paul Sweeney

"Danish biotechnology company Genmab wants to buy Dutch drug maker Maris for $8 billion as they develop a treatment for head and neck cancer, with Maris shares surging up to 37%."

The potential acquisition of Dutch drug maker Maris by Danish biotech giant Genmab represents a bullish M&A catalyst in the healthcare sector. Driven by the development of a new cancer treatment for head and neck cancers, Maris shares have already surged by 37%, reflecting strong market enthusiasm.